BGIM
TEVA icon

Brandywine Global Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Brandywine Global Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-500
Closed -$8K – 882
2019
Q1 		$8K Hold
500
– – ﹤0.01% 800
2018
Q4 		$8K Hold
500
– – ﹤0.01% 769
2018
Q3 		$11K Hold
500
– – ﹤0.01% 782
2018
Q2 		$13K Hold
500
– – ﹤0.01% 822
2018
Q1 		$9K Buy
+500
New +$9.76K ﹤0.01% 844

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brandywine Global Investment Management's TEVA Position: Q2 2019 in Review

Brandywine Global Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 500 shares — an estimated $8K sold.

Brandywine Global Investment Management first reported a position in TEVA in Q1 2018 and held it in 5 quarters. The position peaked at $13K in Q2 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Brandywine Global Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Brandywine Global Investment Management sold 500 Teva Pharmaceuticals shares in Q2 2019, an estimated $8K.
  • Brandywine Global Investment Management first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Brandywine Global Investment Management's Teva Pharmaceuticals position peaked at $13K in Q2 2018.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Brandywine Global Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.